The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Tumour targeting with radiometals for diagnosis and therapy
Abstract
Use of radiometals in nuclear oncology is a rapidly growing field and encompasses a broad spectrum of radiotracers for imaging via PET (positron emission tomography) or SPECT (single-photon emission computed tomography) and therapy via α, β(-), or Auger electron emission. This feature article opens with a brief introduction to the imaging and therapy modalities exploited in nuclear medicine, followed by a discussion of the multi-component strategy used in radiopharmaceutical development, known as the bifunctional chelate (BFC) method. The modular assembly is dissected into its individual components and each is discussed separately. The concepts and knowledge unique to metal-based designs are outlined, giving insight into how these radiopharmaceuticals are evaluated for use in vivo. Imaging nuclides (64)Cu, (68)Ga, (86)Y, (89)Zr, and (111)In, and therapeutic nuclides (90)Y, (177)Lu, (225)Ac, (213)Bi, (188)Re, and (212)Pb will be the focus herein. Finally, key examples have been extracted from the literature to give the reader a sense of breadth of the field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shannon, R. D. (1976) · Acta Crystallographica Section A · doi:10.1107/s0567739476001551 · Cited by 66,145
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Wadas, T. J., Wong, E. H., Weisman, G. R., & Anderson, C. J. (2010) · Chemical Reviews · doi:10.1021/cr900325h · Cited by 924
Synthesis of 11C, 18F, 15O, and 13N Radiolabels for Positron Emission Tomography
Miller, P. W., Long, N. J., Vilar, R., & Gee, A. D. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200800222 · Cited by 894
Potential Technetium Small Molecule Radiopharmaceuticals
Jurisson, S. S., & Lydon, J. D. (1999) · Chemical Reviews · doi:10.1021/cr980435t · Cited by 592
Radiometal-Labeled Agents (Non-Technetium) for Diagnostic Imaging
Anderson, C. J., & Welch, M. J. (1999) · Chemical Reviews · doi:10.1021/cr980451q · Cited by 455
PET imaging with 89Zr: From radiochemistry to the clinic
Deri, M. A., Zeglis, B. M., Francesconi, L. C., & Lewis, J. S. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.08.004 · Cited by 423
Liu, S. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.006 · Cited by 420
Copper radionuclides and radiopharmaceuticals in nuclear medicine
Blower, P. J., Lewis, J. S., & Zweit, J. (1996) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(96)00130-8 · Cited by 406
Radiometals for Combined Imaging and Therapy
Cutler, C. S., Hennkens, H. M., Sisay, N., Huclier-Markai, S., & Jurisson, S. S. (2013) · Chemical Reviews · doi:10.1021/cr3003104 · Cited by 395
Antibody-targeted radiation cancer therapy
Milenic, D. E., Brady, E. D., & Brechbiel, M. W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1413 · Cited by 380
Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
Dijkers, E. C. F., Kosterink, J. G. W., Rademaker, A. P., Perk, L. R., van Dongen, G. A. M. S., Bart, J., de Jong, J. R., de Vries, E. G. E., & Lub-de Hooge, M. N. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060392 · Cited by 334
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
Smith-Jones, P. M., Solit, D. B., Akhurst, T., Afroze, F., Rosen, N., & Larson, S. M. (2004) · Nature Biotechnology · doi:10.1038/nbt968 · Cited by 304
Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer
Hamoudeh, M., Kamleh, M. A., Diab, R., & Fessi, H. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.013 · Cited by 283
Rosenblat, T. L., McDevitt, M. R., Mulford, D. A., Pandit-Taskar, N., Divgi, C. R., Panageas, K. S., Heaney, M. L., Chanel, S., Morgenstern, A., Sgouros, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0382 · Cited by 271
Cu–ATSM: A radiopharmaceutical for the PET imaging of hypoxia
Vāvere, A. L., & Lewis, J. S. (2007) · Dalton Transactions · doi:10.1039/b705989b · Cited by 245
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view
Boswell, C. A., & Brechbiel, M. W. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.04.001 · Cited by 241
Molecular imaging with copper-64
Smith, S. V. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.06.009 · Cited by 230
Radiolabelled RGD peptides for imaging and therapy
Gaertner, F. C., Kessler, H., Wester, H.-J., Schwaiger, M., & Beer, A. J. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2028-1 · Cited by 227
Design and synthesis of 225Ac radioimmunopharmaceuticals.
McDevitt, M. R., Ma, D., Simon, J., Frank, R. K., & Scheinberg, D. A. (2002) · Applied Radiation and Isotopes · doi:10.1016/s0969-8043(02)00167-7 · Cited by 225
Olafsen, T., & Wu, A. M. (2010) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2009.12.005 · Cited by 223
Cooper, M. S., Ma, M. T., Sunassee, K., Shaw, K. P., Williams, J. D., Paul, R. L., Donnelly, P. S., & Blower, P. J. (2012) · Bioconjugate Chemistry · doi:10.1021/bc300037w · Cited by 217
Radiopharmaceutical development of radiolabelled peptides
Fani, M., & Maecke, H. R. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2001-z · Cited by 214
Miederer, M., Scheinberg, D. A., & McDevitt, M. R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.009 · Cited by 210
Advances in Immuno–Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology
Knowles, S. M., & Wu, A. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.4887 · Cited by 209
Nonnatural Amino Acids for Site-Specific Protein Conjugation
de Graaf, A. J., Kooijman, M., Hennink, W. E., & Mastrobattista, E. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800294a · Cited by 205
Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours
Mansi, R., Wang, X., Forrer, F., Waser, B., Cescato, R., Graham, K., Borkowski, S., Reubi, J. C., & Maecke, H. R. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1596-9 · Cited by 205
Perk, L. R., Visser, G. W. M., Vosjan, M. J. W. D., van Walsum, M., Tijink, B. M., Leemans, C. R., & van Dongen, G. A. M. S. (2005) · PubMed · Cited by 205
Zeglis, B. M., & Lewis, J. S. (2011) · Dalton Transactions · doi:10.1039/c0dt01595d · Cited by 198
Cancer radioimmunotherapy with alpha-emitting nuclides
Couturier, O., Supiot, S., Degraef-Mougin, M., Faivre-Chauvet, A., Carlier, T., Chatal, J.-F., Davodeau, F., & Cherel, M. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1803-2 · Cited by 170
Unconventional Nuclides for Radiopharmaceuticals
Holland, J. P., Williamson, M. J., & Lewis, J. S. (2010) · Molecular Imaging · doi:10.2310/7290.2010.00008 · Cited by 167
Chappell, L. L., Dadachova, E., Milenic, D. E., Garmestani, K., Wu, C., & Brechbiel, M. W. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(99)00086-4 · Cited by 159
The Advantages of Nanoparticles for PET
Welch, M. J., Hawker, C. J., & Wooley, K. L. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.061846 · Cited by 142
Hassfjell, S. P., & Brechbiel, M. W. (2001) · Chemical Reviews · doi:10.1021/cr000118y · Cited by 135
Improved in Vivo Stability of Actinium-225 Macrocyclic Complexes
Deal, K. A., Davis, I. A., Mirzadeh, S., Kennel, S. J., & Brechbiel, M. W. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990141f · Cited by 130
Bartholomä, M. D. (2012) · Inorganica Chimica Acta · doi:10.1016/j.ica.2012.01.061 · Cited by 129
Velikyan, I., Sundberg, Å. L., Lindhe, Ö., Höglund, A. U., Eriksson, O., Werner, E., Carlsson, J., Bergström, M., Långström, B., & Максимилианович, Т. В. (2005) · PubMed · Cited by 121
H4octapa: An Acyclic Chelator for 111In Radiopharmaceuticals
Price, E. W., Cawthray, J. F., Bailey, G. A., Ferreira, C. L., Boros, E., Adam, M. J., & Orvig, C. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3024725 · Cited by 116
Self-citationThe role of coordination chemistry in the development of copper and rhenium radiopharmaceuticals
Donnelly, P. S. (2011) · Dalton Transactions · doi:10.1039/c0dt01075h · Cited by 112
Towards translation of 212Pb as a clinical therapeutic; getting the lead in!
Yong, K. J., & Brechbiel, M. W. (2011) · Dalton Transactions · doi:10.1039/c0dt01387k · Cited by 111
Norenberg, J. P., Krenning, B. J., Konings, I. R. H. M., Kusewitt, D. F., Nayak, T. K., Anderson, T. L., de Jong, M., Garmestani, K., Brechbiel, M. W., & Kvols, L. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1264 · Cited by 105
Peptides as Carrier for Tumor Diagnosis and Treatment
Langer, M., & Beck‐Sickinger, A. G. (2001) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011013354877 · Cited by 104
Evaluation of Bifunctional Chelates for the Development of Gallium-Based Radiopharmaceuticals
Ferreira, C. L., Lamsa, E., Woods, M., Duan, Y., Fernando, P., Bensimon, C., Kordos, M., Guenther, K. J., Jurek, P. E., & Kiefer, G. E. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900443a · Cited by 100
Molecular imaging with SPECT as a tool for drug development
Gomes, C. M., Abrunhosa, A. J., Ramos, P., & Pauwels, E. K. J. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.015 · Cited by 100
Targeted therapy using alpha emitters
Vaidyanathan, G., & Zalutsky, M. R. (1996) · Physics in Medicine and Biology · doi:10.1088/0031-9155/41/10/005 · Cited by 93
Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy.
Ting, G., Chang, C.-H., & Wang, H. (2009) · PubMed · Cited by 84
Chappell, L. L., Deal, K. A., Dadachova, E., & Brechbiel, M. W. (2000) · Bioconjugate Chemistry · doi:10.1021/bc990153f · Cited by 82
Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM
Dearling, J. L. J., & Packard, A. B. (2010) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2009.11.004 · Cited by 82
99m-Technetium carbohydrate conjugates as potential agents in molecular imaging
Bowen, M. L., & Orvig, C. (2008) · Chemical Communications · doi:10.1039/b809365b · Cited by 82
Self-citationPET imaging of tumor angiogenesis in mice with VEGF‐A–targeted 86Y‐CHX‐A″‐DTPA‐bevacizumab
Nayak, T. K., Garmestani, K., Baidoo, K. E., Milenic, D. E., & Brechbiel, M. W. (2010) · International Journal of Cancer · doi:10.1002/ijc.25409 · Cited by 71
Brechbiel, M. W., Gansow, O. A., Pippin, C. G., Rogers, R. D., & Planalp, R. P. (1996) · Inorganic Chemistry · doi:10.1021/ic951326p · Cited by 64
68Ga-Labeled Radiopharmaceuticals for Positron Emission Tomography
Shetty, D., Lee, Y., & Jeong, J. M. (2010) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-010-0056-6 · Cited by 62
Chang, A. J., Silva, R. A. D., & Lapi, S. E. (2013) · PubMed · doi:10.2310/7290.2012.00016 · Cited by 59
Costantini, D. L., Villani, D. F., Vallis, K. A., & Reilly, R. M. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069716 · Cited by 58
Ma, D., McDevitt, M. R., Finn, R. D., & Scheinberg, D. A. (2001) · Applied Radiation and Isotopes · doi:10.1016/s0969-8043(01)00062-8 · Cited by 56
Clickable bifunctional radiometal chelates for peptide labeling
Lebedev, A. Y., Holland, J. P., & Lewis, J. S. (2010) · Chemical Communications · doi:10.1039/b924784j · Cited by 53
Ciavarella, S., Milano, A., Dammacco, F., & Silvestris, F. (2010) · BioDrugs · doi:10.2165/11530830-000000000-00000 · Cited by 53
Gustafsson, A., Bäck, T. A., Elgqvist, J., Jacobsson, L., Hultborn, R., Albertsson, P., Morgenstern, A., Bruchertseifer, F., Jensen, H. J., & Lindegren, S. (2011) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2011.07.003 · Cited by 49
Targeting the αvβ3 Integrin for Small-Animal PET/CT of Osteolytic Bone Metastases
Wadas, T. J., Deng, H., Sprague, J., Zheleznyak, A., Weilbaecher, K. N., & Anderson, C. J. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.067140 · Cited by 49
Two 90Y-Labeled Multimeric RGD Peptides RGD4 and 3PRGD2 for Integrin Targeted Radionuclide Therapy
Liu, Z., Shi, J., Jia, B., Yu, Z., Liu, Y., Zhao, H., Li, F., Tian, J., Chen, X. S., Liu, S., et al. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100403y · Cited by 43
Binding and transport of nonferrous metals by serum transferrin
Harris, W. R. (2006) · Springer eBooks · doi:10.1007/bfb0081079 · Cited by 39
Jiang, M., Ferdani, R., Shokeen, M., & Anderson, C. J. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.10.010 · Cited by 38
The Development of Copper Radiopharmaceuticals for Imaging and Therapy
Shokeen, M., & Wadas, T. J. (2011) · Medicinal Chemistry · doi:10.2174/157340611796799177 · Cited by 27
Hoppmann, S., Qi, S., Miao, Z., Liu, H., Jiang, H., Cutler, C. S., Bao, A., & Cheng, Z. (2012) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-012-0890-3 · Cited by 11
Cited by
Metallodrugs in Medicinal Inorganic Chemistry
Mjos, K. D., & Orvig, C. (2014) · Chemical Reviews · doi:10.1021/cr400460s · Cited by 1,289
Self-citationLanthanide Probes for Bioresponsive Imaging
Heffern, M. C., Matosziuk, L. M., & Meade, T. J. (2014) · Chemical Reviews · doi:10.1021/cr400477t · Cited by 1,202
Matching chelators to radiometals for radiopharmaceuticals
Price, E. W., & Orvig, C. (2014) · Chem. Soc. Rev. · doi:10.1039/c3cs60304k · Cited by 1,018
Self-citationProduction of 177Lu for Targeted Radionuclide Therapy: Available Options
Dash, A., Pillai, M. R. A., & Knapp, F. F. (2015) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-014-0315-z · Cited by 386
Potent candidates for Targeted Auger Therapy: Production and radiochemical considerations
Filosofov, D., Kurakina, E., & Radchenko, V. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.12.001 · Cited by 341
Metadata
- Authors
- Ramogida, C. F., & Orvig, C.
- Venue
- Chemical Communications
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2013
- Volume
- 49
- Issue
- 42
- Pages
- 4720
- ISSN
- 1359-7345 (ISSN-L)
- 1364-548X
- OpenAlex
- W2082614986
- Cited by
- 255
- References
- 64
- FWCI
- 17.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
